TY - JOUR T1 - Natural Polymorphisms in <em>Mycobacterium tuberculosis</em> Conferring Resistance to Delamanid in Drug-naïve Patients JF - medRxiv DO - 10.1101/2020.08.07.20167130 SP - 2020.08.07.20167130 AU - Martina L. Reichmuth AU - Rico Hoemke AU - Kathrin Zürcher AU - Peter Sander AU - Anchalee Avihingsanon AU - Jimena Collantes AU - Chloé Loiseau AU - Sonia Borrell AU - Miriam Reinhard AU - Robert J. Wilkinson AU - Marcel Yotebieng AU - Lukas Fenner AU - Erik C. Böttger AU - Sebastien Gagneux AU - Matthias Egger AU - Peter M. Keller A2 - , Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/11/2020.08.07.20167130.abstract N2 - Mutations in the genes of the F420 signaling pathway, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, of Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance. We searched for such mutations among 129 Mtb strains from Asia, South-America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (ddn) that was associated with a critical MIC to delamanid.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Swiss National Foundation (project grant numbers 153442, 310030_166687, 310030_188888, IZRJZ3_164171, IZLSZ3_170834 and CRSII5_177163). The International Epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia- Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. RJW receives support from the Francis Crick Institute, which is funded by UKRI, CRUK, and Wellcome (FC0010218, 104803, 203135). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. This manuscript is not peer-reviewed.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved the study. Written informed consent was obtained at all locations, except in South Africa, where consent was not required for archived samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWGS data from patients Mtb strains shown in Table 1 have been submitted to the NCBI (PRJNA300846; Supplementary Table 1). ER -